Literature DB >> 33328699

Diagnosis, Staging, and Patient Selection for Locoregional Therapy to Treat Hepatocellular Carcinoma.

Zachary T Berman1, Isabel Newton1,2.   

Abstract

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality and the only cancer for which the incidence and mortality are on the rise. Sensitive and specific screening and diagnostic approaches, robust staging regimens, multidisciplinary tumor boards, and patient/family education and engagement in the shared decision-making process help to identify a patient's optimal treatment options. Locoregional therapies have been the mainstay for treating intermediate-stage disease, but they are finding special applications for early and advanced disease. This review discusses the diagnosis of HCC, current accepted staging models, and treatment of HCC, with a focus on locoregional therapies. Thieme. All rights reserved.

Entities:  

Keywords:  hepatocellular carcinoma; locoregional therapy; staging

Year:  2020        PMID: 33328699      PMCID: PMC7732572          DOI: 10.1055/s-0040-1719185

Source DB:  PubMed          Journal:  Semin Intervent Radiol        ISSN: 0739-9529            Impact factor:   1.513


  47 in total

Review 1.  Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis.

Authors:  Daniela Sia; Augusto Villanueva; Scott L Friedman; Josep M Llovet
Journal:  Gastroenterology       Date:  2016-12-30       Impact factor: 22.682

Review 2.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.

Authors: 
Journal:  J Hepatol       Date:  2018-04-05       Impact factor: 25.083

3.  Assessment of the Albumin-Bilirubin (ALBI) Grade as a Prognostic Indicator for Hepatocellular Carcinoma Patients Treated With Radioembolization.

Authors:  Bin Gui; Ashley A Weiner; John Nosher; Shou-En Lu; Gretchen M Foltz; Omar Hasan; Seung K Kim; Vyacheslav Gendel; Naganathan B Mani; Darren R Carpizo; Nael E Saad; Timothy J Kennedy; Darryl A Zuckerman; Jeffrey R Olsen; Parag J Parikh; Salma K Jabbour
Journal:  Am J Clin Oncol       Date:  2018-09       Impact factor: 2.339

4.  Safety and Efficacy of Irreversible Electroporation for the Treatment of Hepatocellular Carcinoma Not Amenable to Thermal Ablation Techniques: A Retrospective Single-Center Case Series.

Authors:  Olivier Sutter; Joyce Calvo; Gisèle N'Kontchou; Jean-Charles Nault; Raffik Ourabia; Pierre Nahon; Nathalie Ganne-Carrié; Valérie Bourcier; Nora Zentar; Fatna Bouhafs; Nicolas Sellier; Abou Diallo; Olivier Seror
Journal:  Radiology       Date:  2017-04-28       Impact factor: 11.105

5.  Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma.

Authors:  Riad Salem; Andrew C Gordon; Samdeep Mouli; Ryan Hickey; Joseph Kallini; Ahmed Gabr; Mary F Mulcahy; Talia Baker; Michael Abecassis; Frank H Miller; Vahid Yaghmai; Kent Sato; Kush Desai; Bartley Thornburg; Al B Benson; Alfred Rademaker; Daniel Ganger; Laura Kulik; Robert J Lewandowski
Journal:  Gastroenterology       Date:  2016-08-27       Impact factor: 22.682

6.  Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy.

Authors:  Lin-Feng Xu; Hong-Liang Sun; Yao-Ting Chen; Jia-Yan Ni; Dong Chen; Jiang-Hong Luo; Jing-Xing Zhou; Ren-Mei Hu; Qi-Yun Tan
Journal:  J Gastroenterol Hepatol       Date:  2013-03       Impact factor: 4.029

7.  Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.

Authors:  Riccardo Lencioni; Josep M Llovet; Guohong Han; Won Young Tak; Jiamei Yang; Alfredo Guglielmi; Seung Woon Paik; Maria Reig; Do Young Kim; Gar-Yang Chau; Angelo Luca; Luis Ruiz Del Arbol; Marie-Aude Leberre; Woody Niu; Kate Nicholson; Gerold Meinhardt; Jordi Bruix
Journal:  J Hepatol       Date:  2016-01-22       Impact factor: 25.083

8.  Albumin-bilirubin versus Child-Pugh score as a predictor of outcome after liver resection for hepatocellular carcinoma.

Authors:  Y-Y Wang; J-H Zhong; Z-Y Su; J-F Huang; S-D Lu; B-D Xiang; L Ma; L-N Qi; B-N Ou; L-Q Li
Journal:  Br J Surg       Date:  2016-03-23       Impact factor: 6.939

9.  Randomized controlled trial of screening for hepatocellular carcinoma.

Authors:  Bo-Heng Zhang; Bing-Hui Yang; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-07       Impact factor: 4.553

10.  Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.

Authors:  Mihir Gandhi; Su Pin Choo; Choon Hua Thng; Say Beng Tan; Albert Su Chong Low; Peng Chung Cheow; Anthony Soon Whatt Goh; Kiang Hiong Tay; Richard Hoau Gong Lo; Brian Kim Poh Goh; Jen San Wong; David Chee Eng Ng; Khee Chee Soo; Wei Ming Liew; Pierce K H Chow
Journal:  BMC Cancer       Date:  2016-11-07       Impact factor: 4.430

View more
  1 in total

1.  Combined screening analysis of aberrantly methylated-differentially expressed genes and pathways in hepatocellular carcinoma.

Authors:  Jisen Cao; Ruiqiang Zhang; Ye Zhang; Yijun Wang
Journal:  J Gastrointest Oncol       Date:  2022-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.